ByeongDeog Park - NeoPharm Chief Pres

All Insiders . Korea . 
Stock . NeoPharm LTD . Stakeholders . Insider . ByeongDeog Park
092730 Stock  KRW 12,000  90.00  0.74%   

Insider

ByeongDeog Park is Chief Pres of NeoPharm LTD
Age 57
Phone82 4 2863 0038
Webhttps://www.neopharm.co.kr

NeoPharm Management Efficiency

The company has return on total asset (ROA) of 0.1067 % which means that it generated a profit of $0.1067 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 13.8195 %, meaning that it generated $13.8195 on every $100 dollars invested by stockholders. NeoPharm's management efficiency ratios could be used to measure how well NeoPharm manages its routine affairs as well as how well it operates its assets and liabilities.
NeoPharm LTD has accumulated 101.79 M in total debt with debt to equity ratio (D/E) of 0.6, which is about average as compared to similar companies. NeoPharm LTD has a current ratio of 4.12, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist NeoPharm until it has trouble settling it off, either with new capital or with free cash flow. So, NeoPharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NeoPharm LTD sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NeoPharm to invest in growth at high rates of return. When we think about NeoPharm's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Gi JangMegaStudyEdu Co
45
BongHo ChoDongKook Pharmaceutical Co
63
Geun AhnMegaStudyEdu Co
44
SoonKang HongDongKook Pharmaceutical Co
N/A
SeungDong ParkMegaStudy Co
62
Seung ParkMegaStudyEdu Co
53
SeIl JeonDongKook Pharmaceutical Co
64
HeungJu OhDongKook Pharmaceutical Co
65
HongKi KimDongKook Pharmaceutical Co
56
Dong KimMegaStudyEdu Co
57
JeWon ParkDongKook Pharmaceutical Co
59
Gi KimMegaStudyEdu Co
50
Jang LeeMegaStudyEdu Co
44
Ji GohMegaStudyEdu Co
52
HeeSoon ParkDongKook Pharmaceutical Co
58
Gi KwonDongKook Pharmaceutical Co
45
JoonHo SongDongKook Pharmaceutical Co
56
Chang LeeMegaStudyEdu Co
50
Wu GuMegaStudyEdu Co
54
SeokBeom HongMegaStudy Co
62
Seung NamMegaStudyEdu Co
54
,Ltd. manufactures and sells skin care products in Korea and internationally. ,Ltd. was founded in 2000 and is headquartered in Daejeon, South Korea. Neopharm is traded on Korean Securities Dealers Automated Quotations in South Korea. NeoPharm LTD (092730) is traded on KOSDAQ in Korea and employs 106 people.

Management Performance

Return On Equity13.82
Return On Asset0.11

NeoPharm Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NeoPharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity13.82
Return On Asset0.11
Profit Margin0.21 %
Operating Margin0.26 %
Current Valuation153.58 B
Shares Outstanding7.99 M
Shares Owned By Insiders38.94 %
Shares Owned By Institutions17.81 %
Price To Earning42.54 X
Price To Sales1.56 X

Other Information on Investing in NeoPharm Stock

NeoPharm financial ratios help investors to determine whether NeoPharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NeoPharm with respect to the benefits of owning NeoPharm security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY